Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

800 patients to help scientists grow liver tumors in the lab

NCT ID NCT04690972

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve understanding and speed up development of future therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help researchers develop better lab models to test new treatments for liver diseases and liver cancer.
What could go wrong
This is an observational study that does not test any treatment directly. The models may not perfectly mimic human disease, and results may take years to impact patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Population with hepato-bilio-pancratic disease (tumor, viral infection, injury)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients * diagnosed with chronic liver disease (viral or not) * diagnosed with at least one liver nodule for which a biopsy is planned as part of the care * for hepatobiliary surgery planned as part of care * for locoregional treatment for HCC is indicated 2. Patients able to receive and understand information relating to the study and give their written informed consent 3. Patients affiliated to the French social security system Exclusion Criteria: 1. Minor patients 2. Patients under legal protection, 3. Patients subject to legal protection or unable to express their consent, 4. Patients in a situation of social fragility, 5. Pregnant or breastfeeding woman, 6. No signing of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease and cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatitis B virus infection hepatitis C virus infection hepatitis D virus infection hepatocellular carcinoma liver cancer liver disorder Liver Neoplasms metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease and cirrhosis Liver cancer Non - alcoholic steatohepatitis Non-alcoholic fatty liver disease Viral hepatitis B Viral hepatitis C Viral hepatitis D

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • PU-PH, Directeur de l'UMR_S1110 Unité Inserm d'affiliation : UMR_S1110

    RECRUITING

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.